MicroRNAs Can Influence Ovarian Cancer Progression by Dysregulating Integrin Activity

Author:

Fasoulakis Zacharias1ORCID,Psarommati Michaela-Zoi2,Papapanagiotou Angeliki3,Pergialiotis Vasilios1ORCID,Koutras Antonios1ORCID,Douligeris Athanasios1,Mortaki Anastasia1,Mihail Antonios1,Theodora Marianna1ORCID,Stavros Sofoklis4,Karakalpakis Defkalion1,Papamihail Maria1ORCID,Kontomanolis Emmanuel N.2,Daskalakis George5ORCID,Antsaklis Panos5ORCID

Affiliation:

1. 1st Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, 115 28 Athens, Greece

2. Department of Obstetrics and Gynecology, Democritus University of Thrace, 681 00 Alexandroupolis, Greece

3. Laboratory of Chemistry Biology, National and Kapodistrian University of Athens, 115 28 Athens, Greece

4. 3rd Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Medical School, Attikon Hospital, 124 62 Athens, Greece

5. 1st Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, 106 76 Athens, Greece

Abstract

Ovarian cancer is a deadly disease that affects thousands of women worldwide. Integrins, transmembrane receptors that mediate cell adhesion and signaling, play important roles in ovarian cancer progression, metastasis, and drug resistance. Dysregulated expression of integrins is implicated in various cellular processes, such as cell migration, invasion, and proliferation. Emerging evidence suggests that microRNAs (miRNAs) can regulate integrin expression and function, thus affecting various physiological and pathological processes, including ovarian cancer. In this article, we review the current understanding of integrin-mediated cellular processes in ovarian cancer and the roles of miRNAs in regulating integrins. We also discuss the therapeutic potential of targeting miRNAs that regulate integrins for the treatment of ovarian cancer. Targeting miRNAs that regulate integrins or downstream signaling pathways of integrins may provide novel therapeutic strategies for inhibiting integrin-mediated ovarian cancer progression.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3